

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross® has been advised by Auro Pharma Inc., Pharmascience Inc. and Sandoz Canada Inc. that the shortages for Auro-Losartan HCT 100 mg/25 mg Tablet (DIN 02423669), pms-Losartan-HCTZ 100 mg/25 mg Tablet (DIN 02392240) and Sandoz Losartan HCT 100 mg/25 mg Tablet (DIN 02313383), respectively, have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 26, 2023**. The following grouping was removed from the Critical Supply Product List **May 25, 2023**.

LOSARTAN POTASSIUM / HYDROCHLOROTHIAZIDE

100 MG / 25 MG TABLET

00002423669	AURO-LOSARTAN HCT	AUR	\$ 0.3146
00002388987	LOSARTAN / HCT	SIV	\$ 0.3146
00002427664	LOSARTAN / HCTZ	SNS	\$ 0.3146
00002389673	MINT-LOSARTAN / HCTZ DS	MPI	\$ 0.3146
00002392240	PMS-LOSARTAN-HCTZ	PMS	\$ 0.3146
00002313383	SANDOZ-LOSARTAN HCT DS	SDZ	\$ 0.3146
00002428547	SEPTA-LOSARTAN HCTZ	SEP	\$ 0.3146
00002241007	HYZAAR DS	ORC	\$ 1.4504

Alberta Blue Cross has been advised by Auro Pharma Inc., Pharmascience Inc. and Sandoz Canada Inc. that the shortages for Auro-Losartan HCT 100 mg/12.5mg Tablet (DIN 02423650), pms-Losartan-HCTZ 100 mg/12.5 mg Tablet (DIN 02392232) and Sandoz Losartan HCT 100 mg/12.5 mg Tablet (DIN 02362449) have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 29, 2023**. The following grouping was removed from the Critical Supply Product List **May 30, 2023**.

LOSARTAN POTASSIUM / HYDROCHLOROTHIAZIDE

100 MG / 12.5 MG TABLET

00002423650	AURO-LOSARTAN HCT	AUR	\$ 0.3082
00002388979	LOSARTAN / HCT	SIV	\$ 0.3082
00002427656	LOSARTAN / HCTZ	SNS	\$ 0.3082
00002392232	PMS-LOSARTAN / HCTZ	PMS	\$ 0.3082

continued next page

continued from previous page

00002362449	SANDOZ LOSARTAN HCT	SDZ	\$ 0.3082
00002297841	HYZAAR	ORC	\$ 1.4202

Alberta Blue Cross has confirmed that the shortage for Supeudol 5 mg Tablet (DIN 00789739) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **June 26, 2023**. The following grouping was removed from the Critical Supply Product List **May 25, 2023**.

OXYCODONE HCL

5 MG TABLET

00000789739	SUPEUDOL	SDZ	\$ 0.1505
00002319977	PMS-OXYCODONE	PMS	\$ 0.1565

Temporary Benefit added to the *ADBL*

Due to the unavailability of Apo-Medroxy 2.5 mg Tablet (DIN 02244726) and Apo-Medroxy 5 mg Tablet (DIN 02244727) manufactured by Apotex Inc. and Teva-Medroxyprogesterone 2.5 mg Tablet (DIN 02221284) and Teva-Medroxyprogesterone 5 mg Tablet (DIN 02221292) manufactured by Teva Canada Limited, Provera 2.5 mg Tablet (DIN 00708917) and Provera 5 mg Tablet (DIN 00030937) manufactured by Pfizer Canada ULC. will be considered temporary benefits for the Alberta Drug Benefit List (ADBL). This grouping was added to the Critical Supply Product List **May 31, 2023**.

As of **May 31, 2023**, all claims for **Provera 2.5 mg Tablet (DIN 00708917)** and **Provera 5 mg Tablet (DIN 00030937)** will be adjudicated to the price published in the most recent Alberta Blue Cross Drug Price List (ABCDPL) until further notice. The *ABCDPL* is available online at ab.bluecross.ca/providers/pharmacy-home.php

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)
403-294-4041 (Calgary and area)
1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area)
FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

